Drug Profile

TCB 007

Alternative Names: Allogeneic gamma delta T cell therapy - TC BioPharm; ImmuniStim^®; TCB-007; Unmodified allogeneic GDTs - TC BioPharm

Latest Information Update: 15 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TC BioPharm
Class T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II COVID 2019 infections

Most Recent Events

13 Oct 2021 Phase-I/II clinical trials in COVID-2019 infections in United Kingdom (Parenteral)
13 Aug 2020 TCB 007 is available for licensing as of 13 Aug 2020. https://www.tcbiopharm.com/about/collaborations
01 Jul 2020 TC BioPharm plans a phase I trial for COVID-2019 infections in the UK in August 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com